7.94
+0.91(+12.94%)
Currency In USD
| Previous Close | 7.03 |
| Open | 7.03 |
| Day High | 7.95 |
| Day Low | 6.6 |
| 52-Week High | 16.63 |
| 52-Week Low | 6.43 |
| Volume | 4.32M |
| Average Volume | 879,922 |
| Market Cap | 933.6M |
| PE | -2.68 |
| EPS | -2.96 |
| Moving Average 50 Days | 8.41 |
| Moving Average 200 Days | 8.84 |
| Change | 0.91 |
If you invested $1000 in 89bio, Inc. (ETNB) since IPO date, it would be worth $381.73 as of December 21, 2024 at a share price of $7.94. Whereas If you bought $1000 worth of 89bio, Inc. (ETNB) shares 3 years ago, it would be worth $640.32 as of December 21, 2024 at a share price of $7.94.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
GlobeNewswire Inc.
Nov 26, 2024 9:05 PM GMT
SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
GlobeNewswire Inc.
Nov 15, 2024 1:05 PM GMT
New post-hoc analyses reinforce pegozafermin’s potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpointsSAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Nov 13, 2024 4:58 AM GMT
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometaboli